tisagenlecleucel

AXP000013.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
CD19
Originator
University of Pennsylvania
Sponsor
Novartis

Names

NameTypeSource
tisagenlecleucelpreferred name, INNcurator, ncit
Kymriahbrandncit
CTL019codencit
CART-19 ambiguoussynonymncit
tisa-celsynonymncit
Tisagenlecleucel-Tsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
replication-incompetent lentiviral vector; murine anti-CD19 scFv, CD8 hinge and transmembrane region, 4-1BB (CD137) costimulatory domain, CD3 zeta signalling domain
Transgenes
anti-CD19 chimeric antigen receptor
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C102758
Wikidata
Q30314624
FDA UNII
Q6C9WHR03O

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2017-08-30approvedKymriahPatients up to 25 with refractory or second-or-later relapse B-cell precursor acute lymphoblastic leukaemia; adults with relapsed or refractory large B-cell lymphoma after two or more lines; adults with relapsed or refractory follicular lymphoma after two or more lines (accelerated approval). Not for primary CNS lymphomasource
EMAEU2018-08-23approvedKymriahPaediatric and young adult patients up to 25 years with B-cell acute lymphoblastic leukaemia that is refractory, in relapse after transplant or in second or later relapse; adults with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma after two or more lines of systemic therapysource
PMDAJP2019-03-26approvedKymriahRelapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia, and relapsed or refractory CD19-positive diffuse large B-cell lymphoma, each limited to patients meeting criteria on prior chemotherapy and on eligibility for or relapse after transplantationsource

Clinical trials (55)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07676877Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell LymphomaRecruitingPhase 12026-12-012027-12-3118Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
NCT04419909Retreatment With CTL019/CTL119WithdrawnPhase 12026-052026-07-150Lymphoma, B-Cell
NCT07378969A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel TherapyRecruiting2026-03-232039-08-3130Secondary Malignancies of T-cell Origin
NCT06785818Long-term Follow up Local Registry Study of Kymriah in South KoreaRecruiting2025-03-122039-12-30500B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
NCT06408194Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesRecruitingPhase 12024-05-132027-0228Acute Lymphoblastic Leukemia; Leukemia
NCT06003179Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With KymriahWithdrawnPhase 12024-04-052026-110Lymphoma, Large B-Cell, Diffuse
NCT05541341Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesRecruiting2023-11-242037-11-23200Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Follicular Lymphoma
NCT05888493A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular LymphomaActive not recruitingPhase 32023-10-022028-07-25109Follicular Lymphoma (FL)
NCT05633615Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 22023-06-122030-06-30396Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Follic Lymph to Diff Large B-Cell Lymphoma; Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
NCT05310591Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of PersistenceRecruitingPhase 1/22023-03-152027-0326Acute Lymphoblastic Leukemia, in Relapse; B Acute Lymphoblastic Leukemia
NCT07039383A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia PatientsCompleted2023-03-012024-06-1879Acute Lymphoblastic Leukemia
NCT05460533A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Active not recruitingPhase 22022-07-122027-0730B-cell Acute Lymphoblastic Leukemia
NCT05037669Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and LymphomaWithdrawnPhase 12022-072025-010Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma
NCT04456023Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)WithdrawnPhase 22022-01-312022-10-310Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05199961Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With TisagenlecleucelTerminated2022-01-252022-09-134Lymphoma, Large B-Cell, Diffuse
NCT04890236Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedEarly phase 12022-01-132024-03-204Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
NCT04156659Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALLWithdrawnPhase 22021-11-302022-11-300B-cell Acute Lymphoblastic Leukemia
NCT05075603Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 12021-07-292024-12-1817DLBCL Arising From Follicular Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma
NCT04855253Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/22021-06-092027-0930DLBCL; DLBCL Arising From Follicular Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma
NCT04161118TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin LymphomaTerminatedPhase 22021-05-122023-02-243Non Hodgkin Lymphoma
NCT07103486A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompleted2021-04-012023-01-31264Diffuse Large B-Cell Lymphoma
NCT05349201CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)Completed2020-12-092021-05-28273Acute Lymphoblastic Leukemia (ALL); Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04225676Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedPhase 22020-10-192021-10-195Acute Lymphoblastic Leukemia
NCT03628053Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic LeukemiaWithdrawnPhase 32020-06-052025-10-080Acute Lymphoblastic Leukemia
NCT04234061Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive not recruitingPhase 22020-04-072027-09-0120Mantle Cell Lymphoma Recurrent
NCT04276870Orphan Indications for CD19 Redirected Autologous T CellsRecruitingPhase 22020-03-122028-03-10133Infants With Very High Risk KMT2A B-ALL; Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation; Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL
NCT05541328Comparison of Clinical Outcomes Among Patients Treated With TisagenlecleucelCompleted2020-02-032021-02-05169Diffuse Large B-cell Lymphoma
NCT04094311Study of Out of Specification for TisagenlecleucelRecruitingPhase 32019-11-212027-03-31200B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma
NCT03876769Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive not recruitingPhase 22019-06-242027-10-19121B-Cell Acute Lymphoblastic Leukemia
NCT03876028Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedPhase 12019-06-112021-11-0110Diffuse Large B-cell Lymphoma
NCT03570892Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin LymphomaCompletedPhase 32019-05-092021-05-06330Non-Hodgkin Lymphoma
NCT03610724Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedPhase 22019-02-152021-07-2734Non-Hodgkin Lymphoma
NCT04134117Tisagenlecleucel In Primary CNS LymphomaCompletedPhase 12019-01-012022-04-1413Primary CNS Lymphoma; Refractory Primary CNS Lymphoma; Relapsed Primary CNS Lymphoma
NCT03642626MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive not recruitingPhase 22018-12-182024-02-09150Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
NCT03568461Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaCompletedPhase 22018-11-122020-11-2498Follicular Lymphoma
NCT03630159Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedPhase 12018-10-092021-07-2012Diffuse Large B-cell Lymphoma
NCT03123939Phase III B in Acute Lymphoblastic LeukemiaCompletedPhase 32017-04-242020-10-1369Acute Lymphoblastic Leukemia
NCT02935543CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALLTerminatedPhase 22016-102018-12-121Leukemia, Acute Lymphoblastic
NCT02906371Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release SyndromeCompletedPhase 12016-082020-03-1180Lymphoblastic Leukemia, Acute, Childhood
NCT02794246CART-19 Post-ASCT for Multiple MyelomaTerminatedPhase 22016-062019-026Multiple Myeloma
NCT02167360Study of Efficacy and Safety of CTL019 in Adult ALL PatientsWithdrawnPhase 22016-062017-01-110B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02640209Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)TerminatedEarly phase 12016-01-292018-10-1520LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
NCT02529813CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedPhase 12015-12-162021-11-0826Acute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia; Blasts 5 Percent or More of Bone Marrow Nucleated Cells; CD19 Positive; Minimal Residual Disease; Non-Hodgkin Lymphoma; Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia
NCT02624258Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin LymphomaTerminatedEarly phase 12015-112019-06-052Hodgkin Lymphoma
NCT02445248Study of Efficacy and Safety of CTL019 in Adult DLBCL PatientsCompletedPhase 22015-07-292022-12-22115Diffuse Large B-cell Lymphoma (DLBCL)
NCT02435849Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedPhase 22015-04-082020-01-2180B-cell Acute Lymphoblastic Leukemia
NCT02228096Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedPhase 22014-08-142018-05-2975B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02135406CART-19 for Multiple MyelomaCompletedPhase 12014-052015-0913Multiple Myeloma
NCT02030847Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 22014-02-272018-04-2642Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
NCT02030834Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ LymphomasCompletedPhase 22014-02-052019-09-1663Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
NCT01747486Dose Optimization Trial of CD19 Redirected Autologous T CellsCompletedPhase 22013-01-022017-12-1342Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
NCT01626495Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaCompletedPhase 1/22011-08-172018-05-0773B Cell Leukemia; B Cell Lymphoma
NCT01551043Allo CART-19 ProtocolTerminatedPhase 12010-092015-052Acute Lymphocytic Leukemia
NCT01029366CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyCompletedPhase 12010-03-172015-0726Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Hematopoietic/Lymphoid Cancer; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
NCT03601442Managed Access Programs for CTL019, TisagenlecleucelAvailableLeukemia; Lymphoma; Off-label Indications
Unconfirmed matches (32)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT07932262An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1Not yet recruitingPhase 1/22027-012028-0636ANCA Associated Vasculitis (AAV); IIM; Immune Thrombocytopenic Purpura; Multiple Sclerosis; Pemphigus Vulgaris (PV); Rheumatoid Arthritis (RA); Systemic Sclerosis (SSc)name in title: CART-19
NCT07890025CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II StudyNot yet recruitingPhase 1/22026-122029-0630Relapsed or Refractory B Cell Acute Lymphoblastic Leukemianame in intervention: CART-19
NCT07371403MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic LeukemiaRecruiting2026-02-202029-0112Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia Not Having Achieved Remission; Acute Lymphoblastic Leukemia Recurrent; Acute Lymphoblastic Leukemia Refractory; Acute Lymphoblastic Leukemia With Failed Remissionname in intervention: CART-19
NCT06839976CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusRecruitingPhase 1/22025-05-062030-02-2824CAR T Cell; CART19; Cell Therapy; Lupus; Lupus Nephritis (LN); SLE; Systemic Lupus Erythematosus (SLE)intervention named: CART-19
NCT06189157MB-CART19.1 in Refractory SLERecruitingPhase 1/22024-08-122027-09-3029SLE - Systemic Lupus Erythematosusname in intervention: CART-19
NCT06508775Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesRecruiting2024-05-052040-12-3140Acute Lymphatic Leukemia; B-cell Non Hodgkin Lymphoma; Childhood Non-Hodgkin Lymphoma; Chronic Lymphatic Leukemia; Melanoma Stage III; Melanoma Stage IV; Pediatric ALLname in intervention: CART-19
NCT06101381CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and LymphomaRecruitingPhase 1/22024-03-212028-1281Leukemia, Acute Lymphoblastic; Lymphoma, Non-Hodgkinintervention named: CART-19
NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLRecruitingPhase 22024-01-032025-06-30100Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemianame in intervention: CART-19
NCT06160362The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)Unknown2023-10-312025-1220Non-hodgkin Lymphoma,B Cellname in intervention: CART-19
NCT06271369Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.Completed2022-08-112023-02-15613Diffuse Large B-cell Lymphomaname in title: tisa-cel
NCT05054257CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaRecruitingPhase 12021-06-022025-06-0110Non-Hodgkin's Lymphoma Refractory; Non-Hodgkin's Lymphoma, Relapsed; Relapsed or Refractory B-cell Acute Lymphoblastic Leukemianame in title: CART-19
NCT04778579Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapyUnknownPhase 22021-05-112024-12-3150Acute Lymphoid Leukemiaintervention named: CART-19
NCT05270772CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALLUnknownPhase 12021-02-252022-07-159CD19+ Relapse/Refractory B-ALLname in intervention: CART-19
NCT04173988Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaUnknownEarly phase 12020-01-092024-10-206ALL, Childhood B-Cellname in intervention: CART-19
NCT04204161A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and LymphomaUnknownPhase 12019-10-082021-10-3030Refractory B-cell Acute Lymphoblastic Leukemia, Childhood; Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood; Relapsed/Refractory B-cell Lymphoma, Childhoodname in intervention: CART-19
NCT03853616MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)Active not recruitingPhase 12018-11-262026-1148Acute Lymphoblastic Leukemia Recurrent; B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory; Chronic Lymphocytic Leukemia Recurrent; Chronic Lymphocytic Leukemia Refractoryname in intervention: CART-19
NCT03685786CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCTUnknownPhase 12018-06-012021-06-0220Leukemia, Lymphocytic, Acute, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cellname in intervention: CART-19
NCT03544021CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)UnknownPhase 1/22018-03-012019-03-0110Leukemia, Lymphocytic, Acutename in intervention: CART-19
NCT03455972Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCTActive not recruitingPhase 1/22018-02-202027-1243Safety and Efficacyname in title: CART-19
NCT03321123MB-CART19.1 in Patients With R/R ALLUnknownPhase 22017-12-012019-07-0110Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractoryname in intervention: CART-19
NCT03896854CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)UnknownPhase 1/22017-10-182024-12-3115Acute Myeloid Leukemiaintervention named: CART-19
NCT03497819Autologous CARTmeso/19 Against Pancreatic CancerUnknownEarly phase 12017-10-012019-10-3110Pancreatic Cancername in intervention: CART-19
NCT03614858CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.UnknownPhase 1/22017-09-012024-12-3120Leukemia, B-cellname in intervention: CART-19
NCT03027739CART-19 Cells For MRD Positive CD19+ ALLUnknownPhase 2/32016-112019-1220Acute Lymphoblastic Leukemiaintervention named: CART-19
NCT03101709The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell LymphomaUnknownPhase 12016-082018-0730B Cell Lymphomaintervention named: CART-19
NCT02924753The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).UnknownPhase 12016-07-182019-0720B-cell Acute Lymphoblastic Leukemianame in intervention: CART-19
NCT02810223Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic LeukemiaUnknownPhase 12016-052017-1220Acute Lymphoblastic Leukemiaintervention named: CART-19
NCT03391726CART-19 Cells for R/R B-cell LymphomaUnknownPhase 2/32016-01-012019-1220Relapsed or Refractory B-cell Lymphomaname in intervention: CART-19
NCT03391739CART-19 Cells For R/R B-ALLUnknownPhase 2/32016-012019-1220Relapsed/Refractory B-cell ALLname in intervention: CART-19
NCT02799550Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALLUnknownPhase 12015-102019-0510Leukemianame in intervention: CART-19
NCT02081937CART-19 Immunotherapy in Mantle Cell LymphomaUnknownPhase 1/22014-032018-122Hematopoietic/Lymphoid Cancer; Mantle Cell Lymphoma; Non-hodgkin Lymphoma,B Cellname in title: CART-19
NCT01864889Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Unknown2013-042017-0412Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Hematopoietic/Lymphoid Cancer; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphomaname in title: CART-19

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40610008Detection of HIV RNA after CAR T-Cell Therapy in a Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patient: Possibility of False Positivity and Clinical Implications.Cancer research and treatment2026name in abstract: tisagenlecleucel
PMID 41252666Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026cited by trial NCT02445248
PMID 41437832Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis.Haematologica2026name in abstract: tisagenlecleucel
PMID 41508112Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure.Journal of hematology & oncology2026name in abstract: tisagenlecleucel
PMID 41536778Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas.Blood neoplasia2026cited by trial NCT03876028
PMID 41747197Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.Blood advances2026name in abstract: tisagenlecleucel
PMID 41765136Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 41856668Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026name in abstract: tisagenlecleucel
PMID 42136039Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates.Pediatric blood & cancer2026name in abstract: tisagenlecleucel
PMID 42178058Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.Transplantation and cellular therapy2026name in abstract: tisa-cel
PMID 42285114Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.The Lancet. Haematology2026name in abstract: tisagenlecleucel
PMID 42285354Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 42341302Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.The New England journal of medicine2026cited by trial NCT02030834
PMID 42469167HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL.Blood advances2026name in abstract: tisagenlecleucel
PMID 42525896Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2026cited by trial NCT02435849
PMID 42629429Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.Bone marrow transplantation2026name in abstract: tisagenlecleucel
PMID 42727020Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults.Blood advances2026name in title: tisagenlecleucel
PMID 38781944Eosinophilic Pleocytosis in the Cerebrospinal Fluid following CAR-T Cell Therapy for Central Nervous System Lymphoma: A Case for Warning?Acta haematologica2025name in abstract: tisagenlecleucel
PMID 39617098Real-world Outcomes of Commercial Tisagenlecleucel for Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia in Japan.Transplantation and cellular therapy2025name in title: tisagenlecleucel
PMID 39817702Role of procalcitonin, C-reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals2025name in abstract: tisagenlecleucel
PMID 39894508Multiple Ulcers with Perforations of the Small Intestine in the Acute Phase of CD19 Chimeric Antigen Receptor T-cell Therapy Possibly Associated with Tocilizumab Administration.Internal medicine (Tokyo, Japan)2025name in abstract: tisagenlecleucel
PMID 39938007Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.Blood2025name in abstract: tisagenlecleucel
PMID 39998830Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.JAMA network open2025name in abstract: tisagenlecleucel
PMID 40085546Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series.Cancer reports (Hoboken, N.J.)2025name in title: tisagenlecleucel
PMID 40090005Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.Blood2025name in abstract: tisagenlecleucel
PMID 40203192Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study.Blood advances2025name in abstract: tisagenlecleucel
PMID 40246539Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2025name in abstract: tisagenlecleucel
PMID 40377509Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial.Cytotherapy2025name in title: tisagenlecleucel
PMID 40438977CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.Haematologica2025name in abstract: tisagenlecleucel
PMID 40589238Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.British journal of haematology2025name in abstract: tisa-cel
PMID 40690779Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.Blood advances2025name in title: tisagenlecleucel
PMID 40815804Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.Blood advances2025name in abstract: tisagenlecleucel
PMID 40903902Isolated oral CD30+/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy.Molecular therapy : the journal of the American Society of Gene Therapy2025name in abstract: tisagenlecleucel
PMID 41348007Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T-cell persistence in ALL.Hematology. American Society of Hematology. Education Program2025name in abstract: tisagenlecleucel
PMID 41671463Immunotherapy in B-Cell Acute Lymphoblastic Leukemia.Journal of the National Comprehensive Cancer Network : JNCCN2025cited by trial NCT03876769
PMID 37883795CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.Blood2024cited by trial NCT04234061
PMID 38114616Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.European journal of nuclear medicine and molecular imaging2024name in abstract: tisagenlecleucel
PMID 38194692Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.Blood2024cited by trial NCT03568461
PMID 38316549Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.European journal of haematology2024name in abstract: tisagenlecleucel
PMID 38318174Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time.Frontiers in immunology2024name in abstract: tisagenlecleucel
PMID 38359407Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma.Blood advances2024name in abstract: tisagenlecleucel
PMID 38448002[Sequential therapy with inotuzumab ozogamicin followed by CAR T-cell therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia].[Rinsho ketsueki] The Japanese journal of clinical hematology2024name in abstract: tisagenlecleucel
PMID 38552193Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024name in abstract: tisagenlecleucel
PMID 38569863[Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].[Rinsho ketsueki] The Japanese journal of clinical hematology2024name in abstract: tisagenlecleucel
PMID 38594876Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.British journal of haematology2024name in abstract: tisagenlecleucel
PMID 38622139Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.Blood cancer journal2024name in title: tisagenlecleucel
PMID 38735758Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.British journal of haematology2024name in title: tisagenlecleucel
PMID 38895058Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report.EJHaem2024name in abstract: tisagenlecleucel
PMID 38953781A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.Blood cancer discovery2024name in title: tisagenlecleucel
PMID 39069076Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.Transplantation and cellular therapy2024name in abstract: tisagenlecleucel
PMID 39098011[Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation].[Rinsho ketsueki] The Japanese journal of clinical hematology2024name in abstract: tisagenlecleucel
PMID 39108768Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments.Cureus2024name in abstract: tisagenlecleucel
PMID 39252248Transformed follicular lymphoma with laryngeal edema requiring tracheal intubation after tisagenlecleucel treatment: A case report.Medicine2024name in title: tisagenlecleucel
PMID 39304585CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.Annals of hematology2024name in abstract: Kymriah
PMID 39396632Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.Transplantation and cellular therapy2024name in abstract: tisagenlecleucel
PMID 39580601EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy.Scientific reports2024name in abstract: tisagenlecleucel
PMID 39589371Aggressive Lymphoma after CD19 CAR T-Cell Therapy.The New England journal of medicine2024name in abstract: tisagenlecleucel
PMID 39651063Prolonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis in a patient with acute lymphoblastic leukemia.Blood cell therapy2024name in abstract: tisagenlecleucel
PMID 39935222[PET-CT positive lesions suggestive of pseudoprogression during long-term follow-up after complete remission with CAR-T cell therapy].[Rinsho ketsueki] The Japanese journal of clinical hematology2024name in abstract: tisagenlecleucel
PMID 36044388Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results.Blood advances2023cited by trial NCT03630159
PMID 36182104Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study.Transplantation and cellular therapy2023name in title: tisagenlecleucel
PMID 36351239Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.Blood2023name in abstract: tisagenlecleucel
PMID 36399695Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023cited by trial NCT02435849
PMID 36404384Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.International journal of hematology2023name in title: tisagenlecleucel
PMID 36508286Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.Blood advances2023name in abstract: tisagenlecleucel
PMID 36690387Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report.Journal for immunotherapy of cancer2023name in abstract: tisagenlecleucel
PMID 36937957Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation.Frontiers in pediatrics2023name in title: tisagenlecleucel
PMID 36964939Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.European journal of haematology2023name in abstract: tisagenlecleucel
PMID 37027246Clofarabine for Lymphodepletion Before CAR-T-Cell Infusion: A Brief Case Report.Journal of pediatric hematology/oncology2023name in abstract: tisagenlecleucel
PMID 37284193Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma.Frontiers in oncology2023name in abstract: tisagenlecleucel
PMID 37303362Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.Cureus2023name in abstract: tisa-cel
PMID 37400640CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.Nature medicine2023name in abstract: tisagenlecleucel
PMID 37659694Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.Transplantation and cellular therapy2023name in abstract: tisa-cel
PMID 37708442Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias.Leukemia & lymphoma2023name in abstract: tisagenlecleucel
PMID 37842456Anti-CD19 Chimeric Antigen Receptor T Cell Therapy With Tisagenlecleucel for Secondary Central Nervous System Lymphoma: A Case Series.Cureus2023name in title: tisagenlecleucel
PMID 38022532Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.Frontiers in immunology2023cited by trial NCT04855253
PMID 34233446Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.Haematologica2022name in abstract: tisagenlecleucel
PMID 34727319Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.Frontiers of medicine2022name in abstract: tisagenlecleucel
PMID 34767461Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2022name in abstract: tisagenlecleucel
PMID 34852305Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.Transplantation and cellular therapy2022name in abstract: tisagenlecleucel
PMID 34904798Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.The New England journal of medicine2022cited by trial NCT03570892
PMID 34921238Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.Nature medicine2022cited by trial NCT03568461
PMID 35028140Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel.Clinical case reports2022name in title: tisagenlecleucel
PMID 35030634Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.Blood advances2022name in title: tisagenlecleucel
PMID 35167655Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.Blood2022cited by trial NCT02445248
PMID 35337365Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.Experimental hematology & oncology2022cited by trial NCT02445248
PMID 35341689Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2022name in title: tisagenlecleucel
PMID 35349631Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.Blood advances2022cited by trial NCT02640209
PMID 35422096Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.Leukemia2022cited by trial NCT02228096
PMID 35646299Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports).Therapeutic advances in hematology2022name in abstract: tisagenlecleucel
PMID 35724631Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.Acta haematologica2022name in title: tisagenlecleucel
PMID 35850429Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.Transplantation and cellular therapy2022name in title: tisagenlecleucel
PMID 35944603Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma.Transplantation and cellular therapy2022name in abstract: tisagenlecleucel
PMID 35973192Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.Blood advances2022cited by trial NCT03568461
PMID 36084658Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.The Lancet. Haematology2022name in title: tisagenlecleucel
PMID 36466893Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report.Frontiers in immunology2022name in abstract: Kymriah
PMID 36714263Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia.Blood cell therapy2022name in abstract: tisagenlecleucel
PMID 32496443Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia.Journal of pediatric hematology/oncology2021name in abstract: tisagenlecleucel
PMID 33009894Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia.Pediatric blood & cancer2021name in abstract: tisagenlecleucel
PMID 33288485Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.Clinical lymphoma, myeloma & leukemia2021cited by trial NCT03570892
PMID 33417474Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2021cited by trial NCT02906371
PMID 33472856Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.Journal for immunotherapy of cancer2021name in title: tisagenlecleucel
PMID 33496754Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.Blood advances2021cited by trial NCT02228096
PMID 33608749Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.European journal of clinical pharmacology2021name in abstract: tisagenlecleucel
PMID 34166502CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.Blood2021name in abstract: tisagenlecleucel
PMID 34310745Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.American journal of hematology2021cited by trial NCT02445248
PMID 34322864Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation.British journal of haematology2021name in title: tisagenlecleucel
PMID 34353848Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.Journal for immunotherapy of cancer2021cited by trial NCT02228096
PMID 34432863Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.Blood advances2021cited by trial NCT02228096
PMID 34515338Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.The Cochrane database of systematic reviews2021cited by trial NCT02030834
PMID 34516954Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.The Lancet. Oncology2021cited by trial NCT02445248
PMID 34560014CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.The Lancet. Haematology2021name in abstract: tisagenlecleucel
PMID 34597381Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.Blood advances2021name in title: tisagenlecleucel
PMID 34697176Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment.In vivo (Athens, Greece)2021name in title: tisagenlecleucel
PMID 35111036Acute Lymphoblastic Leukemia Relapse Limited to the Anterior Chamber of the Eye and Treated with Novel CAR T-Cell Therapy.Case reports in ophthalmology2021name in abstract: tisagenlecleucel
PMID 31709501Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.International journal of hematology2020name in title: tisagenlecleucel
PMID 31815579Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2020cited by trial NCT01029366
PMID 31973908Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.American journal of kidney diseases : the official journal of the National Kidney Foundation2020name in abstract: tisagenlecleucel
PMID 32045475Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.Blood advances2020cited by trial NCT02445248
PMID 32074277Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.Blood advances2020cited by trial NCT02445248
PMID 32074609Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median.Acta haematologica2020name in title: tisagenlecleucel
PMID 32271898Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.Blood advances2020cited by trial NCT02445248
PMID 32271899Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.Blood advances2020cited by trial NCT02445248
PMID 32298202Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2020cited by trial NCT02640209
PMID 32426735Extracorporeal Membrane Oxygenation as a Bridge to Chimeric Antigen Receptor T-cell Therapy for Severe Refractory Sepsis in the Setting of Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia: A Case Report.Critical care explorations2020name in abstract: tisagenlecleucel
PMID 32448949Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.International journal of clinical oncology2020name in title: tisagenlecleucel
PMID 32589970Hyper-CVAD: a regimen for all seasons.The Lancet. Haematology2020cited by trial NCT03876769
PMID 32744738Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.American journal of hematology2020name in abstract: tisagenlecleucel
PMID 30309857FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research2019name in title: tisagenlecleucel
PMID 30489654Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis.Journal of clinical apheresis2019name in abstract: tisagenlecleucel
PMID 30501490Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.The New England journal of medicine2019cited by trial NCT02445248
PMID 30670684The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.Blood cancer journal2019name in abstract: tisagenlecleucel
PMID 31332046Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.Blood advances2019cited by trial NCT02445248
PMID 31606419Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.The Lancet. Oncology2019cited by trial NCT02435849
PMID 29385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.The New England journal of medicine2018cited by trial NCT02435849
PMID 29669777False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.Blood2018name in title: tisagenlecleucel
PMID 29669947Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.JCI insight2018cited by trial NCT02135406
PMID 30178481Neurotoxicity after CTL019 in a pediatric and young adult cohort.Annals of neurology2018cited by trial NCT01626495
PMID 30190371Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research2018name in title: tisagenlecleucel
PMID 30275568Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.Nature medicine2018name in abstract: CTL019
PMID 30572564Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.International journal of molecular sciences2018name in abstract: tisagenlecleucel
PMID 29226764Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.The New England journal of medicine2017cited by trial NCT02030834
PMID 26813675Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.Blood2016cited by trial NCT01747486
PMID 27166358Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.Blood2016name in abstract: CTL019
PMID 26352815Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.The New England journal of medicine2015cited by trial NCT02135406
PMID 25317870Chimeric antigen receptor T cells for sustained remissions in leukemia.The New England journal of medicine2014cited by trial NCT01029366
PMID 23527958Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.The New England journal of medicine2013name in abstract: CTL019
PMID 27632680cited by trial NCT01626495
PMID 29925499cited by trial NCT02624258
PMID 31076448cited by trial NCT01029366
PMID 42575986cited by trial NCT02030834

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39410883Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.Expert opinion on drug safety2026name in abstract: tisagenlecleucel
PMID 40665713Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.Cancer research and treatment2026name in title: tisagenlecleucel
PMID 40968610Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study.Cancer research and treatment2026name in abstract: tisagenlecleucel
PMID 41026960Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel.Blood advances2026name in title: tisagenlecleucel
PMID 41038347Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 41138816Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 41344219Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study.Cytotherapy2026name in title: tisagenlecleucel
PMID 41345759Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review.PharmacoEconomics2026name in abstract: tisagenlecleucel
PMID 41391508Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 41396346Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.PharmacoEconomics - open2026name in abstract: tisagenlecleucel
PMID 41401431A Tetrameric Biotin-Avidin Scaffold Using Anti-CD19 (FMC63) Traptavidin Fusion Enables High-Avidity CAR-T Cells for Leukemia Therapy.Bioconjugate chemistry2026name in abstract: Kymriah
PMID 41448297Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.Critical reviews in oncology/hematology2026name in abstract: tisagenlecleucel
PMID 41492445Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.Therapeutic advances in hematology2026name in abstract: tisagenlecleucel
PMID 41496894CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges.Molecular therapy. Nucleic acids2026name in abstract: Kymriah
PMID 41507382Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Bone marrow transplantation2026name in title: tisagenlecleucel
PMID 41529329Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma.Cytotherapy2026name in abstract: tisagenlecleucel
PMID 41544566Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry.Cytotherapy2026name in title: tisagenlecleucel
PMID 41544567Establishing practical predictors of collection efficiency for optimized chimeric antigen receptor T-cell apheresis.Cytotherapy2026name in abstract: tisagenlecleucel
PMID 41546434Brain Microstructural Damage as Potential Biomarker of Immune Cell-Associated Neurotoxicity Syndrome.Journal of neuroimaging : official journal of the American Society of Neuroimaging2026name in abstract: tisagenlecleucel
PMID 41560109Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System.Medicine2026name in abstract: tisagenlecleucel
PMID 41578095The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology2026name in abstract: tisagenlecleucel
PMID 41579860CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.Cell reports. Medicine2026name in title: tisagenlecleucel
PMID 41639434Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.Annals of hematology2026name in title: tisagenlecleucel
PMID 41689916Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma.Cytotherapy2026name in title: tisagenlecleucel
PMID 41701431Value of information analyses for advanced cell therapies: a systematic review.Health economics review2026name in abstract: tisagenlecleucel
PMID 41729209The Use of Targeted Therapy in Pediatric Acute Lymphoblastic Leukemia: Exploring Novel Approaches and Emerging Therapies.Current treatment options in oncology2026name in abstract: tisagenlecleucel
PMID 41735483Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia.Leukemia2026name in title: tisagenlecleucel
PMID 41748023Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 41762956Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy.Cytotherapy2026name in abstract: tisagenlecleucel
PMID 41772123Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Bone marrow transplantation2026name in title: tisagenlecleucel
PMID 41828393Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy.International journal of molecular sciences2026name in abstract: tisagenlecleucel
PMID 41857785A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.Biomarker research2026name in abstract: tisagenlecleucel
PMID 41858754The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia.Molecular therapy. Oncology2026name in abstract: tisagenlecleucel
PMID 41867486Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.Blood neoplasia2026name in abstract: tisagenlecleucel
PMID 41935222Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy.Bone marrow transplantation2026name in abstract: tisagenlecleucel
PMID 41935576Neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 41951449Infections Post-CAR-T Therapy: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.Clinical therapeutics2026name in abstract: tisa-cel
PMID 41953008Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy.Frontiers in immunology2026name in abstract: tisagenlecleucel
PMID 41959729Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients.HemaSphere2026name in abstract: tisagenlecleucel
PMID 41964291Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.Transfusion2026name in abstract: tisa-cel
PMID 42001436Metabolic changes in reticuloendothelial system following Tisagenlecleucel chimeric antigen receptor T cell (CAR-T) therapy using 18F-FDG PET/CT.Hellenic journal of nuclear medicine2026name in title: tisagenlecleucel
PMID 42018609Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.Blood advances2026name in abstract: tisagenlecleucel
PMID 42086512Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.American journal of hematology2026name in abstract: tisagenlecleucel
PMID 42109668Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.Frontiers in oncology2026name in title: tisagenlecleucel
PMID 42114808Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 42138782Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma.Advances in therapy2026name in title: tisagenlecleucel
PMID 42173255Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 42245166Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers.Frontiers in pediatrics2026name in abstract: tisagenlecleucel
PMID 42251173Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.Bone marrow transplantation2026name in abstract: tisagenlecleucel
PMID 42257985Drug-associated cytokine release syndrome: a FAERS pharmacovigilance study with complementary transcriptomic analysis.Naunyn-Schmiedeberg's archives of pharmacology2026name in abstract: tisagenlecleucel
PMID 42265809Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL.Stem cell research & therapy2026name in abstract: tisagenlecleucel
PMID 42269079Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.Blood advances2026name in abstract: tisagenlecleucel
PMID 42279369Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience.Cancers2026name in abstract: tisagenlecleucel
PMID 42297689Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status.Endocrinologia, diabetes y nutricion2026name in abstract: tisa-cel
PMID 42329247Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.Oncology (Williston Park, N.Y.)2026name in abstract: tisagenlecleucel
PMID 42341926Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 42359427Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves.Cureus2026name in abstract: tisagenlecleucel
PMID 42381271Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database.Japanese journal of clinical oncology2026name in abstract: tisagenlecleucel
PMID 42428526Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.PeerJ2026name in title: tisagenlecleucel
PMID 42449670Real-World Dermatologic Adverse Events of CAR T-Cell Therapy: A Decade-Wide Disproportionality Analysis of the FDA Adverse Event Reporting System.Cancers2026name in abstract: tisagenlecleucel
PMID 42527721Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing.Current oncology reports2026name in abstract: tisagenlecleucel
PMID 42556536Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 42568509CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.Frontiers in immunology2026name in abstract: tisagenlecleucel
PMID 42583745Real-World Data from a Single-Center, Large Academic Centralized Manufacturing of CD19 CAR T Cells in an Industry Partnership.Human gene therapy2026name in abstract: tisagenlecleucel
PMID 42610412Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.Haematologica2026name in title: tisagenlecleucel
PMID 42636161T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.Blood2026name in abstract: CTL019
PMID 42642819Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis From Korea.Journal of Korean medical science2026name in title: tisagenlecleucel
PMID 42645791Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL.Hematology reports2026name in abstract: tisagenlecleucel
PMID 42650392Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study.Children (Basel, Switzerland)2026name in title: tisagenlecleucel
PMID 42660975Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.Leukemia2026name in title: tisa-cel
PMID 42663433InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.European journal of haematology2026name in abstract: tisa-cel
PMID 42675139Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.Leukemia2026name in title: tisagenlecleucel
PMID 42732974Could Mixed CAR T-Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel?American journal of hematology2026name in title: tisagenlecleucel
PMID 42777835Host immune biomarkers associated with infection risk after CAR T-cell therapy.The Journal of infection2026name in abstract: tisagenlecleucel
PMID 42790202Transient suppression of fibrinolytic potential during cytokine release syndrome after chimeric antigen receptor T-cell therapy in B-cell malignancies.Thrombosis research2026name in abstract: tisagenlecleucel
PMID 42844744Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review.Journal of investigative medicine : the official publication of the American Federation for Clinical Research2026name in abstract: tisagenlecleucel
PMID 42844780CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital.Acta clinica Belgica2026name in abstract: tisagenlecleucel
PMID 42896626Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis.Transplantation and cellular therapy2026name in title: tisa-cel
PMID 42906792Predictors and Outcomes of Immune Effector Cell- Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B Cell Non-Hodgkin Lymphoma.Transplantation and cellular therapy2026name in abstract: tisagenlecleucel
PMID 42908664Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database.Frontiers in pharmacology2026name in abstract: Kymriah
PMID 42926043Allogeneic stem cells transplantation in children, adolescents and young adults previously treated by tisagenlecleucel for B-cell precursor acute lymphoblastic leukemia: a French retrospective SFGM-TC study.Transplantation and cellular therapy2026name in title: tisagenlecleucel
PMID 42938906Longitudinal Flow Cytometric Profiling of CAR-T and Endogenous T Cells Following CD19 CAR-T Therapy.Cancers2026name in abstract: tisagenlecleucel
PMID 42951655[CAR-T cell therapy for acute lymphoblastic leukemia: current landscape and novel developments].[Rinsho ketsueki] The Japanese journal of clinical hematology2026name in abstract: tisagenlecleucel
PMID 42968286Long-term outcomes and immune reconstitution after tisagenlecleucel in relapsed or refractory large B-cell lymphoma: a single-institution retrospective study in Japan with over 3 years follow-up.Journal of clinical and experimental hematopathology : JCEH2026name in title: tisagenlecleucel
PMID 43010892Impaired ex vivo T-cell expansion before leukapheresis is associated with out-of-specification tisagenlecleucel manufacturing in pediatric CD19+ALL.Frontiers in immunology2026name in title: tisagenlecleucel
PMID 43019612Model-predicted fludarabine exposure and outcomes after tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia.Cytotherapy2026name in title: tisagenlecleucel
PMID 43026080Secondary cancer after CAR-T cell therapy: A French pharmacovigilance analysis.Therapie2026name in abstract: tisagenlecleucel
PMID 43026256Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition.Bone marrow transplantation2026name in abstract: tisagenlecleucel
PMID 39316713The present and future of CAR T-cell therapy for adult B-cell ALL.Blood2025name in abstract: tisagenlecleucel
PMID 39415689Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas.Haematologica2025name in title: tisagenlecleucel
PMID 39418599Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.Blood advances2025name in abstract: tisagenlecleucel
PMID 39562721Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.Leukemia2025name in abstract: tisagenlecleucel
PMID 39666878Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.Blood cancer discovery2025name in abstract: tisagenlecleucel
PMID 39680322Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example.Oncology and therapy2025name in abstract: tisagenlecleucel
PMID 39680351Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R/R LBCL and poor prognostic factors.International journal of hematology2025name in title: tisagenlecleucel
PMID 39704157Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome.Haematologica2025name in abstract: tisa-cel
PMID 39779930T cell malignancies after CAR T cell therapy in the DESCAR-T registry.Nature medicine2025name in abstract: tisagenlecleucel
PMID 39846935Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome.Cytotherapy2025name in abstract: tisagenlecleucel
PMID 39883946Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.Blood advances2025name in abstract: tisagenlecleucel
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 41183747Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma.Transplantation and cellular therapy2026name in title: CART-19

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P30CA016520Pediatric Oncology ProgramUNIVERSITY OF PENNSYLVANIAGRUPP, STEPHAN A.2021–2026name in abstract: tisagenlecleucel
P30CA016672Stem Cell Biology & Cellular Therapy ProgramUNIVERSITY OF TX MD ANDERSON CAN CTRSHPALL, ELIZABETH J2019–2026name in abstract: tisagenlecleucel
R01CA309280Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumorsCHILDREN'S HOSP OF PHILADELPHIAMA, LEYUAN2026–2026name in abstract: Kymriah
R37CA250661Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cellsHACKENSACK UNIVERSITY MEDICAL CENTERZAKRZEWSKI, JOHANNES2022–2026name in abstract: Kymriah
UH3CA283652Next generation T cell therapies for mutant KRAS solid tumorsUNIVERSITY OF PENNSYLVANIACARRENO, BEATRIZ M.2025–2026name in abstract: Kymriah
UG3CA283652Next generation T cell therapies for mutant KRAS solid tumorsUNIVERSITY OF PENNSYLVANIACARRENO, BEATRIZ M.2023–2024name in abstract: Kymriah
ZIABC011780Clinical development of mechanism-based lymphoma therapiesDIVISION OF BASIC SCIENCES - NCISTAUDT, LOUIS2024–2024name in abstract: tisagenlecleucel
U01CA232361Defining and overcoming intrinsic T cell dysfunction to enable pediatric immunotherapyCHILDREN'S HOSP OF PHILADELPHIAGRUPP, STEPHAN A.2019–2019name in abstract: tisagenlecleucel
U54CA232568Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersCHILDREN'S HOSP OF PHILADELPHIAMACKALL, CRYSTAL2018–2018name in abstract: tisagenlecleucel
Unconfirmed matches (2)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
P01CA214278Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19UNIVERSITY OF PENNSYLVANIAJUNE, CARL H.2017–2026name in title: CART-19
R01CA288473Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome ModulationUNIVERSITY OF PENNSYLVANIAFACCIABENE, ANDREA2025–2026name in title: CART-19

Notes

Lentiviral anti-CD19 (FMC63) 4-1BB CAR. CART-19 also used generically for other CD19 CARs (ambiguous).

How to cite

tisagenlecleucel (AXP000013.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000013.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.